Investing.com - Financial Markets Worldwide
📈 Fed's first cut since 2020: Time to buy the dip? See Tech-focused stock picksUnlock AI Picks

AbbVie's pan-genotypic regimen of glecaprevir/pibrentasvir shows 98% cure rate in late-stage study in HCV-positive patients with chronic kidney disease

Published 11/15/2016, 09:17 AM
AbbVie's pan-genotypic regimen of glecaprevir/pibrentasvir shows 98% cure rate in late-stage study in HCV-positive patients with chronic kidney disease
ABBV
-
  • Results from a Phase 3 clinical trial, EXPEDITION-4, assessing AbbVie's (NYSE:ABBV) investigational pan-genotypic HCV regimen of glecaprevir/pibrentasvir (G/P) in patients with severe chronic kidney disease (CKD) chronically infected with the hepatitis C virus (HCV) showed a cure rate of 98%. The data will be presented today at The Liver Meeting in Boston.
  • EXPEDITION-4 enrolled 104 subjects including 85 who were receiving dialysis at enrollment, 20 with compensated cirrhosis and 44 who were not cured with sofosbuvir with ribavirin or interferon with ribavirin, with or without sofosbuvir.
  • The study showed treatment with G/P delivered a 98% (n=102/104) cure rate (SVR12) following 12 weeks of treatment. In a modified intent-to-treat analysis (excluding subjects who did not achieve SVR for reasons other than virologic failure), the cure rate was 100% (n=102/102).
  • HCV is common in CKD patients, with a prevalence of up to 80% in some regions of the world. As many as 500K Americans have both chronic HCV and CKD.
  • G/P is a once-daily fixed-dose combination of 300 mg of glecaprevir, an NS3/4A protease inhibitor and 120 mg of pibrentasvir, an NS5A inhibitor. Its development is ongoing.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.